伊布替尼按治疗线数及停药后结局:慢性淋巴细胞白血病3期分析
整合RESONATE和RESONATE-2两项3期研究,分析271例非del(17p)慢性淋巴细胞白血病患者,其中初治136例、复发/难治135例。伊布替尼在0线和1/2线亚组的中位无进展生存期未达到,≥3线为40.6个月;总缓解率初治和复发/难治均为92%。停药后复发/难治患者中位总生存期9.3个月,初治未达到,较早线数治疗结局更好。
要点
- 伊布替尼治疗0线和1/2线患者的中位无进展生存期未达到,≥3线为40.6个月。
- 初治和复发/难治患者总缓解率均为92%,缓解深度随时间增加。
- 停药后复发/难治患者中位总生存期9.3个月,初治未达到。
核心结论
- 在整合分析中,伊布替尼在慢性淋巴细胞白血病患者中与良好的无进展生存期和总生存期相关,且不论既往治疗线数如何,总缓解率均较高。
- 伊布替尼停药后结局最好的是在较早线数接受伊布替尼治疗的患者。
研究设计与样本
- 整合分析两项单药伊布替尼的多中心3期研究:RESONATE(PCYC-1112)纳入复发/难治慢性淋巴细胞白血病患者,RESONATE-2(PCYC-1115)纳入无del(17p)的初治慢性淋巴细胞白血病患者。
- 共纳入271例接受伊布替尼治疗的非del(17p)慢性淋巴细胞白血病患者,其中初治136例,复发/难治135例。
- 中位随访时间:初治36个月,复发/难治44个月。
主要发现
- 0线和1/2线既往治疗亚组的中位无进展生存期未达到,≥3线患者为40.6个月。
- 所有亚组的中位总生存期均未达到。
- 总缓解率初治为92%,复发/难治为92%,缓解深度随时间增加。
- 不良事件及因不良事件导致的伊布替尼停药在患者组间相似。
- 大多数患者(64%)仍在接受治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Data were analyzed from two multicenter phase 3 studies of single-agent ibrutinib: RESONATE (PCYC-1112) in patients with R/R CLL and RESONATE-2 (PCYC-1115) in patients with treatment-naive (TN) CLL without del(17p). This integrated analysis included 271 ibrutinib-treated non-del(17p) patients with CLL (136 TN and 135 R/R). Median progression-free survival (PFS) was not reached for subgroups with 0 and 1/2 prior therapies but was 40.6 months for patients with ≥3 therapies (median follow-up: TN, 36 months; R/R, 44 months). Median overall survival (OS) was not reached in any subgroup. Overall response rate (ORR) was 92% in TN and 92% in R/R, with depth of response increasing over time. Adverse events (AEs) and ibrutinib discontinuation due to AEs were similar between patient groups. Most patients (64%) remain on treatment. OS following discontinuation was 9.3 months in R/R patients (median follow-up 18 months, n = 51) and was not reached in TN patients (median follow-up 10 months, n = 30). In this integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR regardless of prior therapies in patients with CLL. The best outcomes following ibrutinib discontinuation were for patients receiving ibrutinib in earlier lines of therapy.
引用
- O'Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019. PMID: 30767298. doi:10.1002/ajh.25436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。